icon
An official government website affiliated with the Government of the Kingdom of Saudi Arabia.
icon Thu 25 Jun 2026
Beta version
icon
Official Saudi government website domains end with gov.sa

All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.

icon
Government websites use the protocol. HTTPS for encryption and security.

All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.

icon
Registered with the Digital Government Authority under number:
20250831619
Suggestions

Use of bisphosphonates among women and risk of atrial fibrillation

Use of bisphosphonates among women and risk of atrial fibrillation

icon 2024-02-21

Objective To assess the association between atrial fibrillation and flutter and use of bisphosphonates for osteoporosis among women.

Design Population based case-control study, using medical databases from Denmark.

Setting Northern Denmark.

Participants 13586 patients with atrial fibrillation and flutter and 68054 population controls, all with complete hospital and prescription history.

Main outcome measure Adjusted relative risk of atrial fibrillation and flutter.

Results 435 cases (3.2%) and 1958 population controls (2.9%) were current users of bisphosphonates for osteoporosis. Etidronate and alendronate were used with almost the same frequency among cases and controls. The adjusted relative risk of current use of bisphosphonates compared with non-use was 0.95 (95% confidence interval 0.84 to 1.07). New users had a relative risk of 0.75 (95% confidence interval 0.49 to 1.16), broadly similar to the estimate for continuing users (relative risk 0.96, 95% confidence interval 0.85 to 1.09). The relative risk estimates were independent of number of prescriptions and the position of the atrial fibrillation and flutter diagnosis in the discharge record, and were similar for inpatients and outpatients.

Conclusion No evidence was found that use of bisphosphonates increases the risk of atrial fibrillation and flutter.

Source: BMJ 2008;336:813-816

Use of bisphosphonates among women and risk of atrial fibrillation
icon

Warning date

2008-04-20